Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results

BACKGROUND: In an attempt to improve low density lipoprotein-cholesterol (LDL-C) level control in patients ineffectively treated with statins, we evaluated the effectiveness of a fixed-dose combination (FDC) of 10 mg rosuvastatin and ezetimibe and its relation to the timing of drug administration. M...

Full description

Bibliographic Details

Published in:	Cardiology Journal
Main Authors:	Karolina Obońska, Michał Kasprzak, Kamila Tymosiak, Tomasz Fabiszak, Magdalena Krintus, Jacek Kubica
Format:	Article
Language:	English
Published:	Via Medica 2021-02-01
Subjects:	hypercholesterolemia fixed-dose secondary prevention timing of administration adherence apolipoprotein B lipoprotein(a)
Online Access:	https://journals.viamedica.pl/cardiology_journal/article/view/69258